中等度から重度の潰瘍性大腸炎の成人患者におけるエトラシモドの観察研究 (ENDEAVOUR-UC)
A MULTI-CENTER, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS (ENDEAVOUR-UC)
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod.
All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer.
The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Arizona
-
Mesa、Arizona、アメリカ、85206
- Reddy GI Associates
-
-
California
-
La Jolla、California、アメリカ、92037
- Scripps Clinic Torrey Pines
-
Los Alamitos、California、アメリカ、90720
- United Medical Doctors
-
-
Colorado
-
Littleton、Colorado、アメリカ、80120
- Rocky Mountain Gastroenterology
-
-
Florida
-
Kissimmee、Florida、アメリカ、34741
- Digestive and Liver Center of Florida Kissimmee
-
Lutz、Florida、アメリカ、33558
- Gastro Florida
-
Orlando、Florida、アメリカ、32806
- Orlando Health/Digestive Health Institute
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University Medical Center
-
Chicago、Illinois、アメリカ、60611
- Feinberg School of Medicine Northwestern University
-
Naperville、Illinois、アメリカ、60540
- Suburban Gastroenterology Ltd
-
-
Maryland
-
Chevy Chase、Maryland、アメリカ、20815
- MGG Group Co., Inc., Chevy Chase Clinical Research
-
Glen Burnie、Maryland、アメリカ、21061
- Woodholme Gastroenterology Associates PA
-
-
New Jersey
-
Marlton、New Jersey、アメリカ、08053
- Virtua Health
-
-
New York
-
New York、New York、アメリカ、10016
- NYU Langone Health
-
New York、New York、アメリカ、10075
- Lenox Hill Hospital, Northwell Health
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology
-
Charlotte、North Carolina、アメリカ、28211
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- University of Cincinnati College of Medicine
-
Westlake、Ohio、アメリカ、44145
- Gastro Intestinal Research Institute of Northern Ohio, LLC
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina (MUSC)
-
-
Texas
-
Houston、Texas、アメリカ、77084
- BI Research Center
-
Houston、Texas、アメリカ、77079
- Houston Endoscopy & Research Center
-
San Antonio、Texas、アメリカ、78234
- Brooke Army Medical center
-
Southlake、Texas、アメリカ、76092
- GI Alliance Research
-
-
Washington
-
Tacoma、Washington、アメリカ、98405
- Washington Gastroenterology
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26505
- WVU Medicine J.W Ruby Memorial Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the United States etrasimod prescribing information and independent from the decision to enroll the patient in this study.
説明
Inclusion Criteria:
- Age ≥ 18 years and < 65 years at baseline
- Patients with confirmed diagnosis of UC who are prescribed etrasimod for moderately to severely active UC
- Evidence of a personally signed and dated ICD indicating that the patient (or a legally acceptable representative)has been informed of all pertinent aspects of the study
Exclusion Criteria:
-
The presence of clinical findings suggestive of Crohn's disease
-
Severe extensive colitis evidenced by:
- Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (e.g., colectomy) within 12 weeks
- Current evidence of acute severe UC, fulminant colitis, or toxic megacolon
-
Patients with a stoma or planned UC surgical intervention requiring hospitalization
-
Prior/Concomitant Therapy:
- Any previous exposure to etrasimod, including participation in the etrasimod clinical program
- Any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine, or tioguanine)
- Any co-medication with one of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist; JAKi [filgotinib, tofacitinib, or upadacitinib]) or with any other S1P receptor modulator
-
Unwillingness or inability to download the web-based tool to complete ePROs on a personal device or not capable of using the web-based tool
-
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
エトラシモドを服用している潰瘍性大腸炎の成人患者
|
As provided in real world practice |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with symptomatic remission
時間枠:Week 12
|
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0 |
Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with symptomatic remission
時間枠:Weeks 24, 36, 52
|
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0 |
Weeks 24, 36, 52
|
|
Proportion of patients with symptomatic response
時間枠:Weeks 12, 24, 36, 52
|
Symptomatic response defined as a decrease from baseline ≥ 30% in pMMS composite RBS and SFS |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with symptomatic response
時間枠:Weeks 12, 24, 36, 52
|
Symptomatic response defined as a decrease from baseline ≥ 20% in pMMS composite RBS and SFS |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with clinical remission
時間枠:Weeks 12, 24, 36, 52
|
Clinical remission is defined as a pMMS ≤ 2 points, with no individual subscores > 1 point. |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with steroid-free symptomatic remission (among all patients and among patients in symptomatic remission)
時間枠:Weeks 24, 36, 52
|
Steroid-free symptomatic remission is defined as patients in symptomatic remission who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint |
Weeks 24, 36, 52
|
|
Proportion of patients with steroid-free clinical remission (among all patients and among patients in clinical remission)
時間枠:Weeks 24, 36, 52
|
Steroid-free clinical remission is defined as patients in clinical remission (using a pMMS) who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint |
Weeks 24, 36, 52
|
|
Change from baseline in fatigue
時間枠:Weeks 12, 24, 36, 52
|
Change from baseline in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score Normalization of fatigue is defined as a FACIT Fatigue score ≥ 40.1 |
Weeks 12, 24, 36, 52
|
|
Change from baseline of bowel urgency
時間枠:Weeks 12, 24, 36, 52
|
Change from baseline in bowel urgency on a 0 (no urgency) - 10 (worst possible urgency) numeric rating scale |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with a clinically meaningful improvement in bowel urgency
時間枠:Weeks 12, 24, 36, 52
|
Clinically meaningful improvement in bowel urgency is defined as ≥ 3-point decrease from baseline among patients with baseline bowel urgency score ≥ 3 |
Weeks 12, 24, 36, 52
|
|
Proportion of patients in bowel urgency remission
時間枠:Weeks 12, 24, 36, 52
|
Bowel urgency remission is defined as a bowel urgency score ≤ 1 among patients with a baseline bowel urgency score ≥ 3 and the overall population |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with complete bowel urgency remission
時間枠:Weeks 12, 24, 36, 52
|
Complete bowel urgency remission is defined as a bowel urgency Numeric Rating Scale score = 0 |
Weeks 12, 24, 36, 52
|
|
Change from baseline in abdominal pain
時間枠:Weeks 12, 24, 36, 52
|
Change from baseline in abdominal pain on a 0 (no pain) - 10 (pain as bad as can imagine) numeric rating scale |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with abdominal pain remission
時間枠:Weeks 12, 24, 36, 52
|
Abdominal pain remission is defined as an abdominal pain Numeric Rating Scale score = 0 |
Weeks 12, 24, 36, 52
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- C5041047
- ENDEAVOUR-UC (その他の識別子:Alias Study Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。